Guardant Health Announces Investor Day on September 24, 2025

Guardant Health will host an Investor Day on September 24, 2025, in New York City. The event will feature presentations from the company's leadership team and will be available via live webcast on Guardant Health's website. The event represents an opportunity for investors and stakeholders to engage with the company's vision and developments in cancer screening, monitoring, and treatment enhancement.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced plans to host an Investor Day on September 24, 2025, in New York City. The event, set to commence at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time, will feature presentations from several members of the company's leadership team. Interested parties can access a live and archived webcast of the presentation on Guardant Health's website at [www.guardanthealth.com](http://www.guardanthealth.com). Due to limited capacity, in-person attendance is available by invitation only.

Guardant Health, founded in 2012, is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and AI analytics. The company's tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer.

The Investor Day comes at a time when the cancer diagnostics market is experiencing significant growth, driven by factors such as the rise in cancer incidence and the need for advanced diagnostic technologies. According to a report by SkyQuest Technology Consulting, the global cancer diagnostics market is expected to grow at a CAGR of 9.4% from 2025 to 2032, reaching USD 48.49 Billion by the end of 2032 [2].

In recent developments, Guardant Health's Shield multi-cancer detection blood test received Breakthrough Device designation from the FDA in June 2025, marking a milestone in multi-cancer early detection from a single blood draw. The company also unveiled a comprehensive immunohistochemistry (IHC) testing suite for solid tumors in May 2025, and launched its Hereditary Cancer test, a germline panel covering 82 genes across 12+ tumor types [2].

The event is expected to provide investors and stakeholders with a comprehensive overview of Guardant Health's vision and developments in cancer screening, monitoring, and treatment enhancement.

References:
[1] https://www.stocktitan.net/news/GH/guardant-health-to-host-investor-day-on-september-24-nyqbimm7ejiz.html
[2] https://www.prnewswire.com/news-releases/cancer-diagnostics-market-to-grow-at-a-cagr-of-9-4-from-2025-to-2032--skyquest-technology-consulting-302540953.html